Methods of inducing functional maturation of immature cardiomyocytes derived from induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) by electrically pacing the immature cardiomyocytes according to a pulse profile that induces maturation until the immature cardiomyocytes mature into functionally adult cardiomyocytes.

A method and apparatus for improving transfection efficiency and/or an intra-cellular delivery process in one or more eukaryotic cells is provided. The method includes providing at least one naked agent suitable for transfection and/or intra-cellular delivery. Introducing the at least one naked agent to one or more eukaryotic cells to form a mixture or transfection mixture and allowing the mixture or transfection mixture to undergo a transfection process or intra-cellular delivery process to form one or more transfected or treated eukaryotic cells. The method includes directing pulsed electromagnetic signals provided at any or any combination of a pre-determined frequency, at a pre-determined pulse rate, or at a pre-determined power, at the at least one a naked agent at step (a) prior to creating the mixture or transfection mixture, at the mixture or transfection mixture in step (b), at the mixture or transfection mixture in step (c) and/or at the transfected or treated cell mixture after step (c).

A method and apparatus for improving transfection efficiency in eukaryotic cells including the steps of providing a transfection mixture including an agent associated with at least one amphiphilic construct suitable for transfection. Adding the transfection mixture to one or more eukaryotic cells to form a transfection complex and allowing the transfection complex to undergo a transfection process to form one or more transfected cells. The method also includes the step of directing pulsed electromagnetic signals provided at any or any combination of a pre-determined frequency, at a pre-determined pulse rate, or at a pre-determined power, at the transfection mixture at step (a) prior to creating the transfection complex, at the transfection complex in step (b), at the transfection complex in step (c) and/or at the transfected cell complex after step (c).

A well for electrically stimulating at least one cell. The well includes a bottom portion and comprises an adaptive electrode arrangement for introducing an electric field into the well. The adaptive electrode arrangement includes a pair of electrodes disposed within the well. Each electrode of the pair of electrodes has a distal end and is independently and axially displaceable relative to the other electrode and the bottom portion of the well. The distal end of each electrode of the pair of electrodes is in contact with the bottom portion of the well, ensuring a uniform and constant electric field is applied within the well.

The present invention relates to a cell support including a base material containing a biocompatible substance or a base material having a surface to which the biocompatible substance is imparted, and gelatin particles held by the biocompatible substance of the base material. The cell support can be produced by a method of causing the base material containing a biocompatible substance to hold the gelatin particles. By seeding cells on the cell support and culturing the cells, a cell structure in which a reagent or a drug has been uniformly taken into more cells can be obtained.

Expansion of cytotoxic T lymphocytes (CTLs) is a crucial step in almost all cancer immunotherapeutic methods. Current techniques for expansion of tumor-reactive CTLs present major limitations. The present invention comprises a novel method to effectively produce and expand tumor-activated CTLs using high-voltage pulsed electric fields. Tumor cells were subjected to high-frequency irreversible electroporation (HFIRE) with various electric field magnitudes and pulse widths, or irreversible electroporation (IRE). The treated tumor cells were subsequently cocultured with CD8+ cytotoxic T cells along with antigen-presenting cells. Tumor-activated CTLs can be produced and expanded when exposed to treated tumor cells. The activated CTLs produced with the present invention could be used for clinical applications with the goal of targeting and eliminating tumors.

The present invention relates to a cell-supporting body, including: a base material including a biocompatible substance; and a gelatin particle retained on the base material. The cell-supporting body can be manufactured by a method of retaining a gelatin particle on a base material including a biocompatible substance. By seeding a cell on the cell-supporting body and culturing the cell, a cell structure in which a reagent or an agent is uniformly incorporated into more cells can be obtained.

A systemic human repair and enhancement system that provides stem cell therapy utilizing an apparatus and methods for administering a treatment schedule of non-invasive and drug-free narrow and specific 0.6180 Hz frequency continuous sine wave therapy to the patient's cells. The frequency therapy may be in-vivo and in-vitro applications. The frequency therapy stimulates systemic stem cell production, particularly at a tissue sites having loss of function due to a condition, aging, damage, and or disease. The frequency therapy system encompasses a narrow and specific ultra-low continuous sine wave frequency stimulation therapy that produces one or more of the enhanced cell production, release, viability, proliferation, migration and or engraftment of the human patient's own genetically compatible stem cells, and the therapy enhances the stem cell's secretions thereby safely enhancing the secretion's therapeutic effects during stem cell therapy and simultaneously systemically enhancing the patient's pre-existing cells and tissues.

A cardiac organoid containing 3-D matter of adult human heart tissue.

The present invention falls within the technical field of cell repair, and specifically relates to a method for repairing stem cells and a use thereof. On the basis of the original invention technology, following improvement, in the present invention, pulse wave-treated water having the function of repairing stem cells is obtained by means of pulse wave-treated water having pulse wave sequences with equal widths and unequal intervals, and the method has additive effects on multiple treated samples. Without influencing cell proliferation, a culture system prepared from the pulse wave-treated water can not only reduce the natural apoptosis effect of human umbilical cord mesenchymal stem cells (H-MSC), but also can inhibit injury-induced H-MSC apoptosis, and has a cell repair effect.